Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

• Jefferies 2016 Healthcare ConferenceTuesday, June 7, 2016 at 8:00 a.m. Eastern TimeThe Grand Hyatt Hotel, New York, NY

• JMP Securities 2016 Life Sciences ConferenceWednesday, June 22, 2016 at 10:30 a.m. Eastern TimeThe St. Regis Hotel, New York, NY

Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for dry eye disease. A New Drug Application (NDA) for the post-operative ocular pain indication has been filed with FDA and has a Prescription Drug User Fee Act (PDUFA) target action date of July 24, 2016. A third Phase 3 clinical trial is being conducted for post-surgical ocular inflammation and pain. For glaucoma and ocular hypertension, the Company has completed its End-of-Phase 2 review with the FDA, and the first of two planned OTX-TP (sustained release travoprost) Phase 3 clinical trials is expected to be initiated in the third quarter of 2016. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160602006202/en/

Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
[email protected]
or
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
[email protected]
or
Media
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Sales and Marketing
[email protected]

Source: Ocular Therapeutix, Inc.

You May Also Be Interested In

• BRICS countries rally to counter shocks of power politics, unilateralism: China Daily editorial
• Next Crypto To Explode: STONK Whale Buys 9.3M Tokens as AlphaPepe Gives Retail a Pre-Listing 300x Bet
• Agog-Supported Works Win Two of Three Immersive Prizes at the 83rd Venice International Film Festival